TrialRespiratory research2024

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study.

Pierre-Francois Clot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.